Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reduced decrease » reported decrease (Expand Search), induces decreased (Expand Search), induced increase (Expand Search)
reduced disease » reduce disease (Expand Search), induced disease (Expand Search), related disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reduced decrease » reported decrease (Expand Search), induces decreased (Expand Search), induced increase (Expand Search)
reduced disease » reduce disease (Expand Search), induced disease (Expand Search), related disease (Expand Search)
-
2301
-
2302
-
2303
-
2304
-
2305
Riboflavin inhibits growth and reduces virulence of <i>Cryptococcus neoformans in vitro</i> by membrane disruption and excessive accumulation of reactive oxygen species and exhibit...
Published 2025“…Finally, in mouse models of intranasal and intravenous infection, RF treatment significantly reduced the fungal burden in multiple organs, reduced lung and brain damage, and decreased the levels of plasma interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-4 in the early stage of infection. …”
-
2306
Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity.
Published 2025“…Nonsignificant trends implicate an effect of spaceflight reducing BV/TV, increasing DA, and reducing Tb.N. Data shown are the mean ± standard deviation with a scatter plot (ns: non-significant). …”
-
2307
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2308
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2309
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
2310
-
2311
-
2312
NeuN expression and neuronal apoptosis in Sham and severely injured groups.
Published 2025Subjects: -
2313
-
2314
-
2315
-
2316
-
2317
Pan-cancer analyses of ANGPTL4 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
2318
Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
2319
-
2320